Yet, some nAbs bind to regions otherthan the RBD in S protein to hinder conformational changes for thefusion state.15 Despite the apparent beneficialoutcomes of nAb therapies among COVID-19 patients, limited availabilityof convalescent plasma and the costly production process of monoclonalantibodies restrain access to this treatment.16 In addition, the ongoing evolution of SARS-CoV-2 poses a significantrisk, as mutation accumulation in S protein can lead to immune escape,which can cause reinfections and make nAb therapies as well as vaccinationineffective. The gene discussed is PROS1; the disease is COVID-19.